Bempedoic acid
In stock
180mg
from 41,18 £
In brief
Bempedoic acid lowers LDL cholesterol by inhibiting an enzyme involved in cholesterol production in the liver. It may be included in a cholesterol-lowering plan when additional reduction is needed or statins are unsuitable.
How bempedoic acid works: mechanism of action and metabolism
Bempedoic acid operates through ATP citrate lyase inhibition, an enzyme crucial for early-stage cholesterol production within liver cells. This distinctive mechanism reduces low-density lipoprotein cholesterol synthesis at its source, differing significantly from traditional statins that target later stages in the cholesterol pathway. The medication demonstrates favourable pharmacokinetics after oral administration with rapid absorption into the bloodstream, typically reaching peak concentration within 3-4 hours. Metabolism occurs primarily through liver glucuronidation followed by renal excretion, resulting in a half-life ranging between 15-30 hours suitable for once-daily dosing.
When considering potential interactions, caution applies to concurrent simvastatin usage due to possible myopathy risk elevation. Dietary considerations remain minimal: while food may slightly delay absorption timing, meal consumption doesn't compromise therapeutic efficacy. Importantly, unlike certain statins, no clinically significant cytochrome P450 enzyme interactions necessitate routine monitoring. Understanding this pharmacological profile supports appropriate prescribing decisions, particularly for statin-intolerant individuals requiring alternative LDL-cholesterol reduction strategies within NHS treatment pathways.
Licensed and off-label uses of bempedoic acid
Bempedoic acid is formally indicated as an adjunctive therapy for adults with primary hypercholesterolaemia or mixed dyslipidaemia and is licensed in the UK. Primarily aimed at statin-intolerant individuals, it provides LDL-cholesterol reduction when standard statin regimens prove unsuitable due to adverse effects. In NHS practice context, prescriptions typically follow comprehensive cardiovascular risk assessments where lifestyle modifications and maximally tolerated statins prove insufficient.
In specialist practice it may also be used for:
- Familial hypercholesterolaemia management in specialist tertiary care settings
- Adjunctive therapy preceding PCSK9 inhibitor initiation
Dosage guidelines and adjustments for patients
| Therapy type | Standard UK dosage | Administration guidance |
|---|---|---|
| Bempedoic acid monotherapy (Nilemdo) | 180mg orally once daily | With or without food at any consistent time |
| Fixed combination therapy (Nustendi) | 180mg/10mg once daily (bempedoic/ezetimibe) | Tablet swallowed whole with water |
Standard adult dosing remains consistent across indications: one 180mg tablet daily for Nilemdo monotherapy or one combination tablet for Nustendi treatment. UK prescribing protocols call for evaluation after 4-8 weeks to assess LDL-cholesterol response. The medication requires no specific timing relative to meals but benefits from consistent daily administration schedules. Dose adjustments become unnecessary for mild renal impairment (eGFR above 30 mL/min/1.73 m²) or mild hepatic dysfunction.
However, bempedoic acid prescriptions carry specific precautions:
- Avoidance advised with concurrent simvastatin exceeding 40 mg daily
- Pre-treatment uric acid monitoring suggested for high-risk patients
Administration & storage
Understanding how to take and store bempedoic acid ensures both effectiveness and safety. Here's what you need to know:
Dosage handling
Forget a dose? Take it immediately upon remembering unless your next scheduled dose is near. Never double up to compensate. If accidentally taking too many tablets, contact your GP or NHS 111 promptly. No specific antidote exists, but healthcare providers can monitor for any concerning signs.
Correct storage
Keep bempedoic acid in its original blister packaging at ordinary room temperature. Protect tablets from moisture – avoid leaving containers open or storing in humid spaces like bathrooms. Freezing temperatures also compromise tablet stability.
Organisation & travel
For chronic management, using a days-of-the-week pill organiser prevents missed doses. When travelling, take your original medicine packaging plus the patient leaflet. Airlines allow essential medicines in hand luggage – request a printed prescription from your GP confirming your need for this cholesterol treatment.
Contraindications & precautions
Bempedoic acid suits many but carries important restrictions worth understanding.
Absolute restrictions
This medication must be avoided by those with confirmed allergy or hypersensitivity to any ingredients. Pregnant or breastfeeding individuals should never take bempedoic acid as studies remain insufficient regarding foetal development and drug transfer in milk.
Necessary cautions
Regular uric acid monitoring becomes essential as many users experience elevations – particularly significant for anyone with gout history. Tendon rupture cases have occurred so report new shoulder pain or heel discomfort immediately. Avoid entirely if severe liver disease exists due to clearance concerns.
Special population guidance
For older adults, regular kidney function checks help determine appropriate dosing. Unlike many cholesterol treatments, bempedoic acid hasn't been tested for paediatric hypercholesterolaemia – children should be prescribed alternative lipid-modifying therapies.
Side effects & management
Common and uncommon reactions require different approaches for safe continuation.
Frequently reported issues
Raised uric acid is one of the most common effects. Back pain and joint discomfort also occur, and cold-like respiratory symptoms are reported. Mild digestive upsets including diarrhoea or discomfort after starting treatment remain relatively common.
Potentially severe reactions
Though tendon rupture is rare, any sudden joint weakness demands urgent clinical assessment. Liver enzyme elevations can occur - your GP will advise stopping treatment for persistent significant changes. Unusual fast-fatigue or yellowed skin need immediate medical review.
Practical coping strategies
Persistent muscle issues require ruling out serious rhabdomyolysis via GP-requested blood tests. Stay well-hydrated to minimise gout risk. Report any new adverse effects through the NHS Yellow Card scheme to help build national safety profiles.
Alternatives & comparison
Understanding all UK-approved options aids informed cholesterol management decisions:
| Treatment | Typical LDL reduction | Primary recommendation |
|---|---|---|
| Bempedoic acid (Nilemdo) | 18% | Statin-intolerant patients alone or alongside statin therapy |
| Ezetimibe | 20% | First-line add-on therapy for moderate LDL lowering |
| PCSK9 inhibitors | 50-60% | Specialist referral for genetic or severe uncontrolled cases |
Treatment selection reflects multiple factors. Statin-intolerant individuals often see bempedoic acid as optimal for balancing efficacy with a lower side effect burden than statins typically pose. For the highest-risk patients, such as those with familial hypercholesterolaemia, specialists may combine this newer agent with PCSK9 inhibitors.
Patient support and resources for bempedoic acid users
UK patients accessing bempedoic acid benefit from several specialised support initiatives. HEART UK operates helplines staffed by cardiac nurses and provides downloadable diet guidance for cholesterol management alongside medication use. Educational materials on cholesterol and lifestyle are also available from the NHS and the British Heart Foundation.
For authoritative information, clinicians consult NICE guidance on lipid modification. Patients suspecting treatment side effects can report them via the MHRA Yellow Card scheme.
Frequently asked questions about bempedoic acid
Q: Is alcohol consumption permitted during Nilemdo treatment?
A: Alcohol is not known to interact directly with bempedoic acid, but heavy drinking raises uric acid levels and may add to the risk of gout, so keep within recommended limits.
A: Alcohol is not known to interact directly with bempedoic acid, but heavy drinking raises uric acid levels and may add to the risk of gout, so keep within recommended limits.
Q: What precautions apply for pregnancy or conception planning?
A: This medication is contraindicated – animal studies indicate fetal harm potential. Reliable contraception is mandatory during therapy.
A: This medication is contraindicated – animal studies indicate fetal harm potential. Reliable contraception is mandatory during therapy.
Q: Does bempedoic acid impair driving ability?
A: Bempedoic acid is not expected to affect the ability to drive.
A: Bempedoic acid is not expected to affect the ability to drive.
Q: Can I purchase it without prescription?
A: No. UK medicine regulations classify it as prescription-only (POM), requiring clinician authorisation.
A: No. UK medicine regulations classify it as prescription-only (POM), requiring clinician authorisation.
Q: Why do some clinicians recommend night-time dosing?
A: Dosing schedule flexibility allows alignment with patient routines – no chronobiological imperative exists.
A: Dosing schedule flexibility allows alignment with patient routines – no chronobiological imperative exists.
Guidelines for proper use of bempedoic acid medications
Treatment adherence requires consistent daily timing with water, independent of meals – consider pairing administration with existing routine activities like brushing teeth. Tell your pharmacist about all supplements and over-the-counter medicines you take to prevent interactions.
Proper storage entails keeping tablets in original packaging away from humidity sources like bathrooms. Crucial administration reminders:
- Swallow tablets whole with water
- Never double a dose to make up for a missed one
- Discard unused medication at pharmacy disposal points
Always retain the NHS patient information leaflet (PIL) for reference and promptly report adverse effects using Yellow Card or pharmacist consultation services.
